The insulin dosage market in China has witnessed substantial fluctuations in value since 2013, with a notable rise from $3.5 billion to $5.1422 billion in 2023. The market experienced a significant uptick in 2018, followed by mostly moderate growth rates. The average annual growth rate (CAGR) over the last five years stands at 3.16%, reflecting steady progress despite some yearly variations.
From 2024 onwards, the market is forecasted to grow consistently, with a projected CAGR of 2.84% over the next five years, culminating in an estimated market size of $6.1524 billion by 2028. This longer-term prediction indicates cautious optimism with a cumulative growth rate of 15.03% through 2028.
Future trends to watch for:
- Technological advancements in insulin delivery systems.
- Increased prevalence of diabetes, driving demand.
- Regulatory changes impacting market dynamics.
- Healthcare accessibility improvements in rural areas.
